Business Context and Reporting Period
Processa Pharmaceuticals, Inc. filed this Form 8-K on September 4, 2019, reporting events occurring on August 29, 2019. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial detail provided is that Processa made a "nominal upfront payment" under a new agreement.
Material Changes
On August 29, 2019, Processa entered into a Material Definitive Agreement (License Agreement) with Akashi Therapeutics, Inc. Key terms include:
- Processa obtained an exclusive worldwide license to develop and commercialize products containing or comprising HT-100.
- Future obligations include Development and Regulatory Milestone payments, Sales Milestone payments, and royalties.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks beyond the standard obligations of the new license agreement. The agreement creates contingent future liabilities based on the achievement of development, regulatory, and sales milestones.
Investor Verification Checklist
- Verify the specific dollar amount of the "nominal upfront payment" in the full text of the License Agreement (Exhibit 99.1).
- Review the specific thresholds and payment amounts for the Development, Regulatory, and Sales Milestones.
- Confirm the royalty rates and duration specified in the agreement.
- Assess the current development status of HT-100 to evaluate the likelihood of triggering milestone payments.